文献速递血栓与止血

BIVV001:不依赖血管性血友病因子(VWF)的新型A型血友病凝血因子VIII替代品

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
PubMed 文献 · Blood · 2020-01-01

BIVV001(rFVIIIFc-VWF-XTEN)是一种经生物工程改造的融合蛋白,通过将VWF-D'D3结构域经IgG1 Fc和2个XTEN多肽与rFVIII融合,使FVIII与内源性VWF物理解耦。在小鼠和猴子中,BIVV001给药后血浆FVIII半衰期分别为25-31小时和33-34小时,较既往FVIII产品提高三至四倍。该分子在保持止血功能的同时显著改善药代动力学特性,有望减少给药频率并优化对各类出血的保护。

要点

  • BIVV001使FVIII与内源性VWF解耦,突破VWF介导的半衰期上限(约15-19小时)。
  • 小鼠和猴子中FVIII半衰期分别为25-31小时和33-34小时,提高三至四倍。
  • 多层面蛋白质工程可在保持止血功能的同时显著改善rFVIII药代动力学。

核心结论

  • BIVV001是首个与内源性VWF物理解耦的rFVIII,具有增强的药代动力学特性,有望改变重型A型血友病的治疗模式。

研究设计与样本

  • 临床前研究:在 mice 和 monkeys 中评估BIVV001的药代动力学与止血功能。

主要发现

  • BIVV001给药后血浆FVIII半衰期在小鼠中为25至31小时,在猴子中为33至34小时,代表FVIII半衰期提高三至四倍。
  • BIVV001在保持止血功能的同时显著改善rFVIII药代动力学特性。

关键数值与推荐

  • 内源性VWF使FVIII半衰期上限约为15至19小时。
  • BIVV001给药后FVIII半衰期:小鼠25至31小时,猴子33至34小时,提高三至四倍。

临床怎么用

  • BIVV001有潜力通过减少给药频率、优化对各类出血的保护,改变重型A型血友病的治疗模式。

局限性

  • 数据来自小鼠和猴子临床前研究,尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Factor VIII (FVIII) replacement products enable comprehensive care in hemophilia A. Treatment goals in severe hemophilia A are expanding beyond low annualized bleed rates to include long-term outcomes associated with high sustained FVIII levels. Endogenous von Willebrand factor (VWF) stabilizes and protects FVIII from degradation and clearance, but it also subjects FVIII to a half-life ceiling of ∼15 to 19 hours. Increasing recombinant FVIII (rFVIII) half-life further is ultimately dependent upon uncoupling rFVIII from endogenous VWF. We have developed a new class of FVIII replacement, rFVIIIFc-VWF-XTEN (BIVV001), that is physically decoupled from endogenous VWF and has enhanced pharmacokinetic properties compared with all previous FVIII products. BIVV001 was bioengineered as a unique fusion protein consisting of a VWF-D'D3 domain fused to rFVIII via immunoglobulin-G1 Fc domains and 2 XTEN polypeptides (Amunix Pharmaceuticals, Inc, Mountain View, CA). Plasma FVIII half-life after BIVV001 administration in mice and monkeys was 25 to 31 hours and 33 to 34 hours, respectively, representing a three- to fourfold increase in FVIII half-life. Our results showed that multifaceted protein engineering, far beyond a few amino acid substitutions, could significantly improve rFVIII pharmacokinetic properties while maintaining hemostatic function. BIVV001 is the first rFVIII with the potential to significantly change the treatment paradigm for severe hemophilia A by providing optimal protection against all bleed types, with less frequent doses. The protein engineering methods described herein can also be applied to other complex proteins.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Seth Chhabra E, Liu T, Kulman J, et al. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. Blood. 2020. PMID: 32078672. doi:10.1182/blood.2019001292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。